Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase-A (MAO-A) is considered an important therapeutic target in depression.
|
30712820 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
In men, there was only a weak effect of MAOA-uVNTR on depression.
|
30943524 |
2019 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus 5,7-dimethoxycoumarin prevented the chronic mild stress induced depression in rats through an increase in the expression of heat shock protein-70 and inhibition of monoamine oxidase-A levels.
|
29472774 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nowadays, therapeutic attention on MAOIs engrosses two imperative categories; MAO-A inhibitors, in certain mental disorders such as depression and anxiety, and MAO-B inhibitors, in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29335210 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
MAO-A and MAO-B may be considered as targets for inhibitors to treat neurodegenerative diseases and depression and for managing symptoms associated with Parkinson's and Alzheimer's diseases.
|
29496172 |
2018 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The functional polymorphism of MAOA gene and genes in serotonin signal pathway are associated with depression.
|
28293733 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
MAO-A is considered to be a major factor of neuropsychiatric and depressive disorders.
|
29400049 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further, the review also proposes possible regulatory mechanisms of MAO-A by miRNAs, which leads to better understanding of the pathology of depressive disorders and their potential use as therapeutic agents.
|
30271325 |
2018 |
Depressive disorder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of MAOA first exon mediated the association of SA with current depression, and both methylation levels and SA independently predicted lifetime depression.
|
29600412 |
2018 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results show a significant upregulation of MAOA and TAC1 in the medial area frontopolaris which is a node in the limbic-cortical network and known to be susceptible for gray matter loss and behavioral dysfunction in patients with depression.
|
29478144 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, AME could be a useful lead compound for developing reversible MAO-A inhibitors to treat depression, Parkinson's disease, and Alzheimer's disease.
|
27840401 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Significant binding affinity of ursolic acid was seen with MAO-A, which indicated its potential role in other neurological disorders, for example, Alzheimer's disease and Parkinson disease besides depression.
|
28034283 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings suggest compounds 4 and 11 be considered as new potent and reversible MAO-A inhibitors or useful lead compounds for the developments of MAO inhibitors for the treatment of disorders like depression, Parkinson's disease and Alzheimer disease.
|
28109809 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The second part summarizes the novel regulatory pathways of MAO-A, which have high potential as novel therapeutic targets for depression.
|
29163009 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The docking experiments revealed that the synthesized derivatives were potential inhibitors of MAO-A protein, which plays a central role in managing depression and anxiety disorders.
|
28694764 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We tested depression and anxiety like behaviors of burn C57 mice with the sucrose preference test, forced swimming test (FST), open field test and elevated plus maze test and then detected the MAOA content and MAOA gene transcriptional levels in the hippocampus with western blot analysis and real-time quantitative PCR analysis.
|
28413107 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the precise relationship between sleep and depression and the role of MAOA in this process remains unknown.
|
28365314 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study supports a potential therapeutic use for MAO-A inhibitors in the treatment of depression and anxiety in patients with HD.
|
26825854 |
2016 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study substantiates the involvement of the MAOA and MTHFR polymorphisms in climacteric depression and offers evidence that the COMT and ESR1 genes may also play a role in the susceptibility to depressive mood in postmenopausal women.
|
26620113 |
2016 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, it has been reported that monoamine oxidase A (MAO A, a major neurotransmitter-degrading enzyme) is significantly increased in the brains of human subjects affected with MDD and rats exposed to chronic social defeat (CSD) stress, which is used to model depression.
|
25502632 |
2015 |
Depressive disorder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Here we report on a small-scale (n=44) replication study of MAOA methylation which (a) confirms that female subjects with a history of depression are hypomethylated compared to controls and (b) shows that females are hypermethylated in the same region compared to males.
|
25623016 |
2015 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response.
|
24809685 |
2015 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Hypomethylation of MAOA's first exon region in depression: a replication study.
|
25623016 |
2015 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
For example, MAO-A mRNA is repressed across cancers, yet MAO-A protein and levels of serotonin, a substrate of MAO-A implicated in depression, are paradoxically increased in malignancies, including breast cancer.
|
25152370 |
2014 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
For example, MAO-A mRNA is repressed across cancers, yet MAO-A protein and levels of serotonin, a substrate of MAO-A implicated in depression, are paradoxically increased in malignancies, including breast cancer.
|
25152370 |
2014 |